Alprostadil: an effective antiplatelet agent for calves

Area of Science:

• Veterinary Pharmacology
• Cardiovascular Research
• Hemostasis

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit human platelets, but their efficacy in bovine models is uncertain.
• Calves are utilized in cardiovascular implant research, necessitating an effective antiplatelet agent for this animal model.
• Limited options exist for antiplatelet therapy in calves undergoing cardiovascular research.

Purpose of the Study:

• To evaluate Alprostadil (prostaglandin E1) as a potential antiplatelet agent in calves.
• To determine the efficacy and safety of Alprostadil in inhibiting bovine platelet aggregation.
• To compare the in vitro and in vivo effects of Alprostadil on bovine and human platelets.

Main Methods:

• Alprostadil was administered intravenously to 8 calves, with dosage gradually increased to achieve 50% platelet aggregation inhibition.
• Platelet function, blood pressure, body temperature, and hematologic parameters were monitored.
• In vitro studies assessed Alprostadil's effect on platelet aggregation and cyclic adenosine monophosphate levels in bovine and human blood.

Main Results:

• Alprostadil inhibited platelet aggregation in both bovine and human subjects, with bovine platelets showing greater responsiveness.
• In vivo, a dose of approximately 0.20 micrograms/kg/min achieved 50% platelet inhibition with a minor, transient decrease in blood pressure and no significant adverse effects.
• Platelet inhibition was fully reversible within 24 hours of discontinuing Alprostadil infusion.

Conclusions:

• Alprostadil is a potent inhibitor of bovine platelet aggregation.
• Its favorable safety profile and short half-life make Alprostadil a suitable antiplatelet agent for calves in cardiovascular implant research.
• Alprostadil offers a promising therapeutic option for managing thrombosis risk in bovine models of cardiovascular disease.